INKT:NASDAQMiNK Therapeutics, Inc. analysis
Data as of Sep 11, 2026 - not real-time
- Latest price
- $12.13
- Risk: high
- 9/10High risk
Summary
At $12.13, MiNK Therapeutics, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Across the trailing 30 sessions it gained 16.9%. Momentum indicators put RSI at 58.3 (neutral) with MACD reading bullish. Recent trading has carved out support near $10.82 and resistance around $12.69.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 221.5% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 55.1%, a beta of 0.84 and a maximum drawdown of 47.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 221.5% above today's level.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 55.1%, a beta of 0.84 and a maximum drawdown of 47.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top market events
- MiNK Therapeutics reports encouraging initial data from its ARDS study, narrows net loss, and expands international...
- First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation,...
- The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...
Market outlook
Short term
< 1 yearNeutral
Model confidence2/102 out of 10
Key factors
- Trading above the 200-day average of 11.38
- MACD momentum is positive
- 30-day price change of +16.9%
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Trading above the 200-day average of 11.38
- Analyst targets imply +221.5% versus the current price
- 30-day volatility of 55.1%
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +221.5% versus the current price
- Negative free cash flow
- 30-day volatility of 55.1%
Key metrics
Financial health
P/E Ratio-4.6
ROA-123.84%
P/B Ratio-4.4
Op. Cash Flow$-6830483
Free Cash Flow$-5348023
Industry P/E29.6
Technical analysis
TrendNeutral
RSI58.3
Support$10.82
Resistance$12.69
MA 20$11.51
MA 50$11.18
MA 200$11.38
MACDBullish
VolumeStable
Fear & Greed Index89.98
Valuation
Target Price$39.00
Upside/Downside221.52%
GradeFair
TypeBlend
Risk assessment
Beta0.84
Volatility55.06%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.